BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seventeen analysts that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $142.72.

Several equities analysts have recently weighed in on BNTX shares. Evercore ISI raised shares of BioNTech from an "in-line" rating to an "outperform" rating and raised their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price target for the company. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a report on Monday, December 2nd.

BioNTech Stock Down 0.8 %

Shares of BNTX stock traded down $0.91 during trading hours on Thursday, hitting $112.76. 483,930 shares of the company were exchanged, compared to its average volume of 814,352. The company has a market capitalization of $27.03 billion, a PE ratio of -53.69 and a beta of 0.18. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The business has a 50 day moving average of $114.56 and a two-hundred day moving average of $104.12. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same period in the prior year, the firm earned $0.73 earnings per share. BioNTech's revenue for the quarter was up 38.9% compared to the same quarter last year. Analysts anticipate that BioNTech will post -3.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC increased its position in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after acquiring an additional 111 shares during the period. Blue Trust Inc. lifted its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares during the period. Planning Capital Management Corp increased its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after purchasing an additional 450 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock valued at $465,000 after acquiring an additional 582 shares during the period. Finally, Slow Capital Inc. boosted its stake in BioNTech by 1.2% during the third quarter. Slow Capital Inc. now owns 51,680 shares of the company's stock worth $6,138,000 after acquiring an additional 600 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.